InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Reaches Agreement with ATERA SAS to Aid INM-750 Research in Pre-Clinical Tests
InMed to test INM-750 in vitro, estimates clinical trials for 2018-2020 ATERA SAS to develop 3D skin models to help pre-clinical tests of INM-750 INM-750 being developed to treat skin disease epidermolysis bullosa, with a successful therapy having potential global market of $1 billion InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a biopharmaceutical company focused on identifying and commercializing prescription drugs using non-THC cannabinoids, recently reached a research and development agreement with tissue engineering company ATERA SAS of France (http://nnw.fm/5t7cL). The fundamental benefits of this agreement for InMed, as it eyes a clinical trial program, are a proprietary assessment tool,…







